---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-038933"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-30T23:51:33.941323+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MangoRx launches oral Semaglutide weight-loss treatment 'Slim' at $299/month

## Summary
- Launched oral Semaglutide ODT compounded with Vitamin B6, branded 'Slim', on MangoRx.com.
- Priced at $299 per month; available via MangoRx telemedicine platform with physician review.
- Targets global GLP-1 market projected to grow from $49.3B in 2024 to $157.5B by 2035 (Roots Analysis).
- CEO Jacob Cohen cites growing GLP-1 demand; product aims to boost revenue and market share.
- Oral dissolvable tablet format offers needle-free alternative to traditional injections.

## SEC filing metadata
- accession: 0001493152-24-038933
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315224038933/0001493152-24-038933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315224038933/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-038933
- JSON: https://secwatch.observer/filing/0001493152-24-038933.json
- Plain text: https://secwatch.observer/filing/0001493152-24-038933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.